PCSA vs IQV vs CRL vs ICLR vs MEDP

For growth investors, Medpace Holdings, Inc.

(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). IQVIA Holdings Inc. (IQV) offers the better valuation at 21. 4x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate Processa Pharmaceuticals, Inc. (PCSA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, IQVIA Holdings Inc.

(IQV) is the cheapest at 21. 4x versus ICON Public Limited Company at 50. 3x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 13. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 32x versus Medpace Holdings, Inc. 's 0. 85x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +159. 2%, compared to -98. 3% for Processa Pharmaceuticals, Inc. (PCSA). Over 10 years, the gap is even starker: MEDP returned +1556% versus PCSA's -95. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Medpace Holdings, Inc.

(MEDP) is the lower-risk stock at 1. 02β versus Processa Pharmaceuticals, Inc. 's 2. 22β — meaning PCSA is approximately 118% more volatile than MEDP relative to the S&P 500. On balance sheet safety, ICON Public Limited Company (ICLR) carries a lower debt/equity ratio of 39% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Medpace Holdings, Inc.

(MEDP) is pulling ahead at 20. 0% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Processa Pharmaceuticals, Inc. grew EPS 89. 3% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Medpace Holdings, Inc.

(MEDP) is the more profitable company, earning 17. 8% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus 0. 0% for PCSA. At the gross margin level — before operating expenses — CRL leads at 30. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 32x versus Medpace Holdings, Inc. 's 0. 85x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 13. 1x forward P/E versus 27. 1x for Medpace Holdings, Inc. — 14. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PCSA: 324. 5% to $9. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +1556% 10Y return). Processa Pharmaceuticals, Inc. (PCSA) carries a higher beta of 2. 22 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MEDP: +1556%, PCSA: -95. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PCSA is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock; CRL is a small-cap quality compounder stock; ICLR is a mid-cap quality compounder stock; MEDP is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.